Cargando…
Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients
BACKGROUND: Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760053/ https://www.ncbi.nlm.nih.gov/pubmed/31572498 http://dx.doi.org/10.1186/s13098-019-0475-1 |
_version_ | 1783453805120061440 |
---|---|
author | Tang, Meng-jie Su, Jian‑bin Xu, Tian-li Wang, Xue‑qin Zhang, Dong-mei Wang, Xiao-hua |
author_facet | Tang, Meng-jie Su, Jian‑bin Xu, Tian-li Wang, Xue‑qin Zhang, Dong-mei Wang, Xiao-hua |
author_sort | Tang, Meng-jie |
collection | PubMed |
description | BACKGROUND: Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endogenous islet beta cell function in type 2 diabetic patients. METHODS: Samples were obtained from 271 subjects: 85 drug-naïve type 2 diabetes participants exclusively on lifestyle intervention (N-DM group), 122 type 2 diabetes subjects previously used medications (DM group) and 64 normal controls (NC group). Serum FGF19 concentrations were measured by ELISA. The insulin sensitivity (MI), insulin secretion (AUC(ins)/AUC(glu)) and insulin secretion-sensitivity index-2 (ISSI-2) were also measured in the N-DM and DM. RESULTS: Serum FGF19 levels decreased, in order, from the NC group [median (interquartile range), 245.03 (126.23–317.43) pg/mL] to the N-DM group [170.05 (89.01–244.70) pg/mL] and, finally, to the DM group [142.25 (55.55–187.58) pg/mL] (p for trend < 0.05). Among subjects in the DM group, there was a positive trend in the serum FGF19 concentration; plasma insulin levels at 60 min, 120 min (INS60, INS120, respectively); and area under the insulin curve (AUC(ins)) at two points (r = 0.214, p = 0.025; r = 0.189, p = 0.048; r = 0.188, p = 0.049). However, the differences were no longer observed among the N-DM subjects. Simultaneously, the ISSI-2 was closely related to the serum FGF19 levels (r = 0.297, p = 0.002) among DM subjects. Furthermore, after adjusting for age, sex, duration, therapy and other clinical factors via multiple logistic regression analysis, ISSI-2 was a key independent factor in the levels of FGF19 (β = 0.281, t = 2.557, p = 0.013). CONCLUSIONS: The serum FGF19 level has a close relation with endogenous beta cell function among DM subjects, as assessed by the ISSI-2. As ISSI-2 is higher in N-DM group, FGF19 may be a main protector in dysfunction of beta cell. |
format | Online Article Text |
id | pubmed-6760053 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67600532019-09-30 Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients Tang, Meng-jie Su, Jian‑bin Xu, Tian-li Wang, Xue‑qin Zhang, Dong-mei Wang, Xiao-hua Diabetol Metab Syndr Research BACKGROUND: Fibroblast growth factor 19 (FGF19) takes part in maintaining the balance of glycolipids and may be involved in regulating the secretory activity of islet beta cells in patients with type 2 diabetes. This study aimed to evaluate the relationship between the levels of serum FGF19 and endogenous islet beta cell function in type 2 diabetic patients. METHODS: Samples were obtained from 271 subjects: 85 drug-naïve type 2 diabetes participants exclusively on lifestyle intervention (N-DM group), 122 type 2 diabetes subjects previously used medications (DM group) and 64 normal controls (NC group). Serum FGF19 concentrations were measured by ELISA. The insulin sensitivity (MI), insulin secretion (AUC(ins)/AUC(glu)) and insulin secretion-sensitivity index-2 (ISSI-2) were also measured in the N-DM and DM. RESULTS: Serum FGF19 levels decreased, in order, from the NC group [median (interquartile range), 245.03 (126.23–317.43) pg/mL] to the N-DM group [170.05 (89.01–244.70) pg/mL] and, finally, to the DM group [142.25 (55.55–187.58) pg/mL] (p for trend < 0.05). Among subjects in the DM group, there was a positive trend in the serum FGF19 concentration; plasma insulin levels at 60 min, 120 min (INS60, INS120, respectively); and area under the insulin curve (AUC(ins)) at two points (r = 0.214, p = 0.025; r = 0.189, p = 0.048; r = 0.188, p = 0.049). However, the differences were no longer observed among the N-DM subjects. Simultaneously, the ISSI-2 was closely related to the serum FGF19 levels (r = 0.297, p = 0.002) among DM subjects. Furthermore, after adjusting for age, sex, duration, therapy and other clinical factors via multiple logistic regression analysis, ISSI-2 was a key independent factor in the levels of FGF19 (β = 0.281, t = 2.557, p = 0.013). CONCLUSIONS: The serum FGF19 level has a close relation with endogenous beta cell function among DM subjects, as assessed by the ISSI-2. As ISSI-2 is higher in N-DM group, FGF19 may be a main protector in dysfunction of beta cell. BioMed Central 2019-09-24 /pmc/articles/PMC6760053/ /pubmed/31572498 http://dx.doi.org/10.1186/s13098-019-0475-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tang, Meng-jie Su, Jian‑bin Xu, Tian-li Wang, Xue‑qin Zhang, Dong-mei Wang, Xiao-hua Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
title | Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
title_full | Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
title_fullStr | Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
title_full_unstemmed | Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
title_short | Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
title_sort | serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760053/ https://www.ncbi.nlm.nih.gov/pubmed/31572498 http://dx.doi.org/10.1186/s13098-019-0475-1 |
work_keys_str_mv | AT tangmengjie serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients AT sujianbin serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients AT xutianli serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients AT wangxueqin serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients AT zhangdongmei serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients AT wangxiaohua serumfibroblastgrowthfactor19andendogenousisletbetacellfunctionintype2diabeticpatients |